Preliminary test of anhedonia scale in depression and cannabis use
Psychometric Evaluation of the Dimensional Anhedonia Rating Scale (DARS): A Preliminary Study.
AI Summary
This preliminary human psychometric study asked whether the Dimensional Anhedonia Rating Scale (DARS) can reliably measure reduced ability to experience pleasure in people with co-occurring major depressive disorder (MDD) and cannabis use disorder (CUD). Thirty-five participants completed the DARS alongside established measures of anhedonia, depression, and anxiety. No cannabis or other treatment intervention was tested; the study evaluated questionnaires and their relationships with one another.
The DARS showed a supported four-factor structure, excellent internal consistency, and expected agreement with the Snaith-Hamilton Pleasure Scale (SHAPS), including a reported correlation of Ο = β.64. It also showed good ability to distinguish participants classified as having anhedonia by the SHAPS, with AUC = .81; the study-derived threshold of 65 had approximately .85 sensitivity and .75 specificity. These findings provide preliminary support for using the DARS in this clinical population, but the small sample and preliminary design mean the study cannot establish causation, treatment benefit, or how well the scale generalizes beyond people with both MDD and CUD. This is an abstract-based summary, not a review of the full text.
π‘ Key Findings
π
Original Abstract
Related Research
Similar Studies
More Mental Health research papers you might find interesting.
Brain blood-flow reductions in acute anorexia follow a cortical hierarchy
CBD showed limited adaptive-functioning differences versus placebo in boysβ¦
Resilience linked to depression outcomes and THC positivity
Explore More Research
Stay informed about the latest cannabis science.